Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, discuss how agents such as cilta-cel and ide-cel have affected multiple myeloma management.
Back
Advances With CAR T-Cell Therapy in Multiple Myeloma
Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, discuss continued research and progress with CAR T-cell therapy in multiple myeloma, with updates from ASH 2025.
Advances With CAR T-Cell Therapy in Multiple Myeloma
Episodes
All
All
Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, explain the role of treatment center coordinators in CAR T-cell therapy administration in multiple myeloma.
Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, detail current expectations with manufacturing processes for CAR T-cell therapy.
Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, discuss considerations for bridging therapy ahead of CAR T-cell therapy in multiple myeloma.
Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, detail data for out-of-specification cilta-cel in multiple myeloma, as presented at ASH 2025.
Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, discuss other key CAR T-cell therapy updates to emerge from the 2025 ASH Annual Meeting.
Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, discuss future research directions for CAR T-cell therapy in multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
The OncFive: Top Oncology Articles for the Week of 8/9
3
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
4
Novel Approaches for Hematocrit Control Are Driving Research in Polycythemia Vera
5